Kura Oncology (NASDAQ:KURA) Hits New 1-Year High at $19.60

Kura Oncology, Inc. (NASDAQ:KURAGet Free Report) shares hit a new 52-week high during trading on Wednesday . The stock traded as high as $19.60 and last traded at $19.60, with a volume of 4227480 shares trading hands. The stock had previously closed at $13.42.

Analyst Ratings Changes

Several research firms have recently weighed in on KURA. Wedbush lowered their price target on Kura Oncology from $40.00 to $37.00 and set an “outperform” rating on the stock in a report on Friday, November 3rd. StockNews.com started coverage on Kura Oncology in a research report on Thursday, October 5th. They issued a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Friday, December 8th. Finally, Mizuho initiated coverage on shares of Kura Oncology in a report on Friday, December 22nd. They issued a “buy” rating and a $26.00 price target on the stock. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.17.

Get Our Latest Analysis on KURA

Kura Oncology Stock Performance

The company has a quick ratio of 16.71, a current ratio of 16.71 and a debt-to-equity ratio of 0.02. The business’s 50-day simple moving average is $12.86 and its two-hundred day simple moving average is $10.71. The firm has a market cap of $1.34 billion, a price-to-earnings ratio of -9.28 and a beta of 0.87.

Kura Oncology (NASDAQ:KURAGet Free Report) last announced its quarterly earnings data on Thursday, November 2nd. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.06. As a group, sell-side analysts expect that Kura Oncology, Inc. will post -2.09 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Troy Edward Wilson sold 91,052 shares of the stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $20.23, for a total transaction of $1,841,981.96. Following the completion of the transaction, the chief executive officer now owns 559 shares of the company’s stock, valued at approximately $11,308.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 5.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc lifted its holdings in Kura Oncology by 4.0% during the 4th quarter. Legal & General Group Plc now owns 22,373 shares of the company’s stock worth $278,000 after buying an additional 857 shares in the last quarter. Guggenheim Capital LLC raised its holdings in shares of Kura Oncology by 3.8% in the 1st quarter. Guggenheim Capital LLC now owns 24,671 shares of the company’s stock valued at $397,000 after purchasing an additional 914 shares in the last quarter. MetLife Investment Management LLC raised its holdings in shares of Kura Oncology by 2.7% in the 4th quarter. MetLife Investment Management LLC now owns 35,896 shares of the company’s stock valued at $445,000 after purchasing an additional 946 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Kura Oncology by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,760 shares of the company’s stock valued at $291,000 after purchasing an additional 975 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Kura Oncology by 4.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 26,871 shares of the company’s stock valued at $245,000 after purchasing an additional 1,115 shares in the last quarter.

About Kura Oncology

(Get Free Report)

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.

See Also

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.